PolyNovo Limited’s Chief Financial Officer, Jan Gielen, is leaving the company after nearly eight years to join Vitrafy Life Sciences Limited as its new CFO. His departure is set to take effect on **15 January 2027**, marking the end of his tenure at PolyNovo. The move follows Vitrafy Life Sciences’ expansion efforts in the life sciences sector.
PolyNovo (ASX:PNV) is appointing two independent non-executive directors to its board ahead of the 2026 Annual General Meeting. The move aims to strengthen governance and oversight as the company prepares for its upcoming shareholder meeting. The directors will bring external expertise to support strategic decision-making.
PolyNovo reports a record annual revenue of **$150 million** for fiscal year 2026. The Australian biotech company specializes in developing treatments for neurodegenerative diseases. The milestone reflects strong financial performance amid ongoing clinical trials for its lead drug candidates.
PolyNovo secures **Therapeutic Goods Administration (TGA) clearance** for its **NovoSorb MTX** wound-care products in **4 mm and 6 mm sizes**, expanding on the March approval for the 2 mm version. The company also announces a **trading halt** as part of its disclosure process.
